Interdisciplinary clinical boards (ICB) on chronic inflammatory diseases discuss complicated and multidisciplinary cases with inflammatory conditions among experts in their discipline. Medically specialized large language models (LLMs) are finding increasingly widespread use among physicians to answer clinical question...
M. Ronicke, L. Sollfrank, Ioannis Sagonas et al.· Scientific Reports· 0 citations
Interleukin (IL)-23p19 inhibitors are increasingly used in immune-mediated inflammatory diseases (IMIDs), particularly inflammatory bowel disease (IBD). Almost half of patients show inadequate response, partly due to pharmacokinetic (PK) variability. However, a comprehensive overview of their PK parameters is lacking,...
I. A. Pool, Alise D. E. de Groot, R. J. Keizer et al.· Clinical Pharmacokinetics· 0 citations
It is suggested that VCS exerts broader immunosuppressive effects than CsA, supporting its repurposing as a therapeutic strategy and highlighting SLP-76 as a potential immunoregulatory target in IBD.
L. Loges, Michael Gabel, Annkathrin Knauss et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.